PAREXEL Strengthens Commitment to Global Biopharmaceutical Workforce
News Apr 10, 2015
PAREXEL International Corporation has announced three new academic programmes at the PAREXEL Academy. The offerings span the globe and are designed to prepare students for careers in the biopharmaceutical industry:
• Bachelor of Science Degree in Clinical Research - Offered in partnership with the Medical School Berlin, in Berlin, Germany, the degree programme features courses specific to clinical research. Courses range from ethics in health and medicine to conducting clinical trials. Several courses are taught by PAREXEL experts.
• Postgraduate Certificate in Clinical Trial Management - In cooperation with Salem State University in Salem, Massachusetts, the postgraduate certificate programme features a broad-based curriculum in various components of the full life cycle of drug development.
• Joint Programme for Clinical Research and Clinical Trial Management - In collaboration with Kyoto Pharmaceutical University in Kyoto, Japan, the joint programme provides fifth grade undergraduate students an introductory, seven-week course in clinical research and clinical trial management.
"PAREXEL is committed to developing the biopharmaceutical industry's next-generation global workforce," said Heidrun Bruchmann, Ph.D., Senior Director, PAREXEL Academy. "Through the PAREXEL Academy, we tailor educational and degree programmes with our partners to equip the future health sciences workforce with a holistic and cross-functional foundation in clinical research and clinical trial management."
For more than a decade, the PAREXEL Academy has designed and implemented a wide range of learning programmes tailored to enable clinical research management practices for learners inside and outside of PAREXEL. The PAREXEL Academy has locations in the United States, Europe, and Asia. Since inception, approximately 1,000 students have graduated from the Academy's programmes, including its undergraduate Bachelor of Science programme.
Mary L. Churchill, Ph.D. Associate Provost, Innovation and Partnerships, Salem State University, commented that "Salem State is committed to providing students with programmes that are both foundational and workforce-aligned. Through our partnership with the PAREXEL Academy, we create programmes to give students the specific tools needed to succeed post-graduation in biopharmaceutical research."
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
£70M Meant for Cancer Drug Development is Reassigned to Prepare for BrexitNews
At the end of last year, the Health Committee held a meeting to discuss Brexit, more specifically the impact this will have on the discovery, development and regulation of medicines, medical devices and biopharmaceuticals.READ MORE